Lilly Unveils $13 Billion Medicine Foundry to Bolster U.S. Drug Supply Chain
Lilly has unveiled the Lilly Medicine Foundry, a major new facility aiming to bolster the U.S. medication supply chain. The project, a significant investment in Indiana's LEAP District, is set to create jobs and drive innovation in pharmaceutical production.
The Lilly Medicine Foundry will span 1.2 million square feet, housing state-of-the-art research, manufacturing, and technology facilities. It's the largest single investment in active pharmaceutical ingredient production in the U.S., with Lilly committing around $13 billion.
The facility is designed to be a hub for a range of molecular therapies, integrating research, process development, and advanced technology. It's expected to generate over 2,000 construction jobs during development and sustain approximately 400 high-skill positions once operational in 2027.
Governor Mike Braun and Lilly CEO Dave Ricks highlighted the facility's strategic importance. They emphasized the national benefit of reducing reliance on overseas pharmaceutical production, a goal aligned with America's efforts to strengthen its pharmaceutical independence.
The Lilly Medicine Foundry marks a significant milestone for Indiana's innovation ambitions and the U.S. pharmaceutical industry. It's set to drive economic growth, attract high-tech industries, and enhance the nation's medication supply chain resiliency.
Read also:
- Americans Lose Insurance Under New Tax Legislation, Affecting 10 Million Citizens
- Trump Signs Law Defunding Planned Parenthood, Threatening Healthcare Access for Millions
- Historian Ute Frevert Explores Germans' Emotional Bond With Constitutions
- Milei's Ideological Approach Reshapes Argentina's Foreign Policy
